Go to Contents
CEO Message Targeting, Attacking, and Eradicating Cancers®

TOP

CEO Message

Dear Stakeholders and Investors, Wishing you a happy new year, and warm greetings as we begin 2019! As we welcome a new year, I would like to take this opportunity to look ahead and think about what this year may bring us.

2019 is a year of tremendous importance for SillaJen. With regards to our main business, the Phase III clinical trial in liver cancer “PHOCUS” is running smoothly and we are expecting to receive the Futility Analysis result this year. The result holds significant meaning as it is the very first result from PHOCUS, which shall enable the assessment of Pexa-Vec’s medical values, and the revaluation of its reliability and expectations in global markets.

Our business has reshaped operations and revamped the organization in order to fortify clinical developments, which should be of our prime focus. As expanding pipelines to a wider range of tumors would directly lead to an enhancement in the enterprise value of SillaJen, such organizational changes were critically necessary. Consequently, we have greatly expanded our Clinical Management teams including Clinical Operations, Data Management, R&D Strategy & Planning, and Assay Development. We believe that a strong clinical management will in turn strengthen our future research and clinical developments.

Recently, many biopharmaceutical companies listed on KOSDAQ had their market values highly rated. With recent exciting news on licensing out to global Big Pharma, they have led to a change in the atmosphere of the capital market. The biopharma industry is truly garnering an increasing amount of attention as next-generation growth markets. We feel proud to have contributed visibly to such establishment of the industry, and we feel a great sense of responsibility to repay great expectations from the market with excellent results.


We will maintain a strategic perspective and set bold goals in tackling our corporate social responsibility of ameliorating the suffering of cancer patients and improving their quality of life, setting an example as a model venture firm for all other newly starting Biopharma companies.

While the primary role of Biopharma firms is to continuously expand research scopes and get value assessments in the capital market based on their research results, we believe that we should also strive to make this a better, healthier world for all. With this belief in our heart, we will continue to grow to be a pioneer in the industry. Please keep watching SillaJen as we move in this direction.

In closing, please accept my very best wishes to you and your family for a prosperous 2019.

서명